Bio Integrates 2020 – Monday 16 November, Live online
Biotechnology
Wed, 11/11/2020 - 08:00
Falmouth, UK, 11th November 2020 / Sciad Newswire / Leading Japanese manufacturer of fermentation and bioreactor systems, Ab
Mon, 09/11/2020 - 07:30
Integrated lead optimisation to advance APEIRON’s Cbl-b inhibitor development programme APN431
Inhibitors discovered at Domainex via virtual and fragment screening
Tue, 13/10/2020 - 12:30
Join the debate that determines MedTech’s future
Wed, 07/10/2020 - 07:30
Bournemouth, UK, 7th October 2020 / Sciad Newswire / Solentim is pleased to announce the adoption of its
Wed, 30/09/2020 - 07:30
NanoSyrinx is the first company to engineer ‘nanosyringes’, a selective non-viral peptide and protein delivery system identified in an undisclosed organism.
Mon, 28/09/2020 - 10:30
New opinion piece from Watson-Marlow Fluid Technology Group launched today
Mon, 21/09/2020 - 10:00
Eileen Regan joins Examen as Chief Commercial Officer as the company expands to meet the needs of the UK’s top fertility clinics
Thu, 17/09/2020 - 15:19
Falmouth, UK, 17th September 2020 / Sciad Newswire / Single-use technology has been touted as the latest and most promising development in bioprocessing technolog
Thu, 17/09/2020 - 12:00
The Huntington Study Group (“HSG”), a world leader in clinical research for Huntington’s Disease (HD), announces a partnership with Prilenia Therapeutics, a clinical stage biotech company led by Michael R. Hayden, MD, PhD, to conduct PRidopidine Outcome On Function in Huntington’s Disease (PROOF-HD) clinical study. PROOF-HD is a global Phase 3, randomized, double-blind, placebo-controlled, parallel arm, multicenter study evaluating the efficacy and safety of pridopidine in patients with early stage HD.